Articles-of-manufacturing comprising an object having a surface and at least a first layer of a first therapeutically active agent being deposited onto at least a continuous portion of the surface, wherein at least 50 weight percents of the first layer is the first therapeutically active agent in a crystalline form are disclosed. Methods utilizing such articles-of-manufacturing for treating medical conditions are also disclosed. Processes of preparing the articles-of-manufacturing by contacting a surface of the object with a solution containing the therapeutically active agent, without cooling the surface to a temperature below a temperature of the solution, are also disclosed.

The present invention includes multifunctional compositions, methods and binding systems to provide disinfecting and deodorizing coatings for hard and soft surfaces, inorganic and organic solid surfaces and particulate media and other related substrates, including human and animal skin and skin lesions; to provide neutralizing functions for malodors generated by both human, animal and industrial fluids and solid wastes; and to provide neutralizing and degrading functions for nuisance and noxious chemicals. The present invention provides compositions and methods for producing disinfecting, oxidizing and enzyme-inhibiting fluids enabling preparation of durable, stable biocidal and deodorizing coatings and media which can be widely used for biological agent control, prevention and elimination of odors, and degradation of noxious agents susceptible to chemical oxidation, and which take forms that are inoffensive to users and offer high convenience.

The invention provides a medical device comprising a hydrophobic analog of a medicament known to inhibit cell proliferation and migration. The invention also provides a method of treating a narrowing in a body passageway comprising placing an implantable medical device comprising a hydrophobic analog of a medicament known to inhibit cell proliferation and migration. The medicaments can be incorporated within or coated on the device. The invention further provides hydrophobic analogs of medicaments known to inhibit cell proliferation and migration.

Compositions and methods for the surface appearance of the skin a subject are provided. An injectable composition comprising at least hyaluronic acid or a salt thereof; and an effective amount of at least mepivacaine or a salt thereof are provided. The hyaluronic acid optionally has an average molecular weight ranging from 50,000 to 10,000,000 Daltons, and may be crosslinked hyaluronic acids, non-crosslinked hyaluronic acids, or a combination, in some embodiments. The compositions and methods of the present invention are useful for treating and preventing the cutaneous signs of chronological aging and/or induced by external factors such as stress, air pollution, tobacco or prolonged exposure to ultraviolet (UV) exposure, impaired surface appearance of the skin, impaired viscoelastic or biomechanical properties of the skin, and/or the long-lasting filling of volume defects of the skin.

A method and device for local delivery of a water-insoluble therapeutic agent to the tissue of a normal or diseased body lumen is disclosed. An expandable structure of a medical disposable device, such as a balloon of a balloon catheter, is coated with a non-durable coating which comprises poly(HEMA) complexed with iodine and has a substantially water-insoluble therapeutic agent dispersed therein. The medical disposable device is inserted into a body lumen, and expanded to contact the non-durable coating against the body lumen and deliver the substantially water-insoluble therapeutic agent to the body lumen tissue.

The disclosed invention is a device and method of use for gauze utilized in the treatment of hemorrhage. In an embodiment the device combines clotting factor concentrator gauze and urea in order to slow hemorrhage and prevent hemorrhage induced coagulopathy. In an embodiment, the gauze is comprised of a first layer comprised of gauze and a second layer embedded with urea. The urea reacts spontaneously when it comes into contact with water, and undergoes an endothermic reaction. This endothermic reaction cools the smaller blood vessels exposed from soft tissue trauma, causing enhanced platelet activity as well as vasoconstriction to minimize the bleeding that occurs before and after the clotting cascade is activated over the entire wound surface.

The present invention provides compositions for extended release of an active ingredient, comprising a lipid-saturated matrix formed from a biodegradable polymer. The present invention also provides methods of producing the matrix compositions and methods for using the matrix compositions to provide controlled release of an active ingredient in the body of a subject in need thereof.

Methods for inhibiting stenosis, obstruction and/or calcification of a heart valve following implantation in a vessel having a wall are disclosed. In one aspect the method includes providing a bioprosthetic heart valve mounted on an elastical stent; treating the bioprosthetic heart valve with a tissue fixative; coating the stent and the bioprosthetic valve with a coating composition including one or more therapeutic agents; implanting the bioprosthetic valve into the vessel in a diseased natural valve site; eluting the coating composition from the bioprosthetic valve; and inhibiting stenosis, obstruction and/or calcification of the bioprosthetic heart valve by preventing the attachment of stem cells to the bioprosthetic heart valve, the stem cells circulating external and proximate to the bioprosthetic heart valve by activating nitric oxide production (i) in the circulating stem cells, (ii) in an endothelial cell lining covering the bioprosthetic heart valve tissue, (iii) or both.

The present invention relates to pharmaceutical compositions comprising an inorganic salt and hydroxyurea or a pharmaceutically acceptable salt thereof. The composition is in the form of doped crystals so that the hydroxyurea, or the pharmaceutically acceptable salt thereof, is included in the crystal lattice of the inorganic salt. The invention also relates to use of a pharmaceutical composition according to the invention as a medicament.

The present invention relates to a dermal filler composition based on crosslinked hyaluronic acid, wherein the hyaluronic acid is crosslinked with a high molecular weight polyethylene glycol diglycidyl ether (PEGDE) crosslinker having an average number of CH.sub.2CH.sub.2O repetitive units of 8 to 90. Furthermore, the present invention relates to a method for preparing said dermal filler composition and its use for cosmetic purposes.